What is the discovery stage in drug development?
Discovery is where a program goes from a biological hypothesis to a real, dosable molecule. You start with a target you believe drives a disease, and you finish with one or more lead compounds (or a biologic sequence) that hit that target with the right potency, selectivity, and early developability to justify the cost of preclinical work. Everything downstream, the toxicology, the IND, the clinical trials, inherits whatever you got right or wrong here.
The stage is really a sequence of go/no-go decisions rather than one continuous effort. Is the target druggable and worth pursuing? Do we have an assay that reliably reports activity? Did the screen produce hits that are real and not artifacts? Can chemistry turn a weak, messy hit into a clean, optimized lead? Can we make and purify enough protein to study the mechanism? Each question is a place where programs quietly die, which is exactly why teams outsource the parts where a specialist runs them faster and cleaner than building the capability in-house.
Discovery spans every modality. Small molecules, monoclonal antibodies, peptides, oligonucleotides, ADCs, and cell and gene therapy candidates all have a discovery phase, even though the actual bench work looks different in each. A small-molecule program leans on medicinal chemistry and crystallography; a biologics program leans on protein engineering, display libraries, and developability screening. BioBridgeX covers all of them, across every therapeutic area.
What CRO and CDMO services are included in discovery?
Discovery sourcing breaks into eight service categories, and most programs touch several of them, sometimes in sequence and sometimes in parallel.
Target ID and validation establishes that your target actually matters to the disease, using CRISPR knockout and knockdown screens, RNAi, target expression and pathway analysis, and genetic association work. Assay development and screening builds the readout you will optimize against (biochemical, cell-based, reporter, or phenotypic assays), checks that it performs and reproduces well, then runs high-throughput screening or fragment-based screening across compound libraries. Hit-to-lead takes confirmed hits, weeds out the false positives, runs dose-response and counter-screens, and narrows a long list down to a few credible chemical series.
Lead optimization is the iterative medicinal-chemistry engine: design, make, test, repeat, improving potency, selectivity, solubility, metabolic stability, and early safety flags across many cycles. Medicinal and synthetic chemistry as a standalone service covers custom synthesis, route scouting, scale-up of research quantities, analog libraries, and analytical characterization. Computational and AI discovery spans structure-based and ligand-based design, molecular docking, free-energy perturbation, generative chemistry, ADMET prediction, and the newer machine-learning platforms that propose and rank candidates.
- Target ID and Validation: CRISPR and RNAi screens, target expression and pathway analysis, genetic and disease-association evidence, druggability assessment
- Assay Development and Screening: biochemical and cell-based assay design, assay qualification (Z-prime, reproducibility), HTS, fragment-based and phenotypic screening
- Hit-to-Lead: hit confirmation, false-positive triage, dose-response, counter-screens, chemical-series selection
- Lead Optimization: iterative design-make-test-analyze cycles improving potency, selectivity, ADME, and developability
- Medicinal and Synthetic Chemistry: custom synthesis, route scouting, analog libraries, research-scale scale-up, analytical characterization
- Computational and AI Discovery: structure- and ligand-based design, docking, FEP, generative models, ADMET and property prediction
- Structural Biology: protein crystallography, cryo-EM, NMR, SPR and biophysical binding studies to guide design
- Protein Sciences and Reagents: construct design, expression, purification, antibody generation, and custom reagent supply
How do you choose a discovery CRO or CDMO?
The first filter is fit to the specific problem, not the size of the logo. A CRO that is excellent at small-molecule HTS may be the wrong choice for a tough membrane-protein structure, and a brilliant antibody-discovery shop is irrelevant to your kinase program. Ask for relevant case studies in your target class and modality, and check whether the scientists you would actually work with have done this exact kind of work before.
For discovery specifically, three things separate a strong partner from a frustrating one. First, scientific judgment: in lead optimization you are paying for the medicinal chemist's instinct about which analogs to make next, not just hands at a bench. Second, turnaround on a design-make-test cycle, because a slow cycle can add months across the dozens of iterations a real program needs. Third, data quality and honesty: you want clean SAR tables, straight reporting of the compounds that failed, and IP terms that leave you owning what you paid to discover.
A few due-diligence items are worth confirming up front: who owns the IP and any platform-derived inventions, how compounds and data get transferred to you, what the assay acceptance criteria are, whether published or peer-reviewed work backs their methods, and how they handle confidentiality on a target you may not want disclosed. Price matters, but in discovery the cost of a slow or low-quality partner is paid in lost program time, which is almost always the more expensive variable.
How long does discovery take and how should you scope it?
Discovery timelines swing widely by modality and by how much is already known, so treat any single number with suspicion. As a rough orientation, a target validation package might run a few months, assay development and a screening campaign commonly take several months to stand up and execute, and a full hit-to-lead through lead optimization effort for a small molecule frequently spans a year or more of iterative chemistry. Biologics discovery has a different shape: antibody campaigns through display or immunization, followed by screening and developability, often run several months to a year before you hold a lead panel.
Scope the work as a staged statement of work with explicit decision gates rather than one open-ended engagement. A clean structure is to scope target validation, then assay development, then screening, then each optimization phase as separate milestones with go/no-go criteria you agree before starting. This keeps spend tied to progress and gives you a natural exit if the biology does not hold up, which in discovery it sometimes will not.
Be precise about what a deliverable actually is. A lead optimization milestone should state the target profile in numbers (potency thresholds, selectivity ratios, solubility, microsomal stability), the number of design-make-test cycles, and exactly which compounds and data you receive. Loose scopes like "optimize the series" are where discovery projects overrun. The more concrete the success criteria, the easier it is to compare quotes from different suppliers on equal terms.
Does discovery work need to be GLP, GMP, or GCP?
Mostly no, and this surprises teams coming from a clinical background. The great majority of discovery research, the screening, the chemistry, the structural biology, the protein production, is research-grade work conducted under good scientific practice and good documentation, but it is not run under GLP. GLP (Good Laboratory Practice) is a regulatory quality system aimed at the safety studies that support an IND, which sit in the IND-enabling stage, not in discovery. GMP and GCP belong even further downstream, to manufacturing and clinical trials respectively.
Quality still matters in discovery, just in a different form. What you want is reproducibility and traceability: qualified assays with documented performance, properly characterized reagents and reference compounds, clean and auditable data capture, and analytical confirmation of compound identity and purity. Many strong discovery CROs work to ISO 9001 or their own quality systems, and sound electronic-notebook practice and chain-of-custody on samples are reasonable to expect.
The GLP line gets blurry at the discovery-to-preclinical handoff. Some early in vitro safety and ADME screening can be done as non-GLP exploratory work in discovery, with the definitive, GLP-compliant versions repeated later for the regulatory package. Knowing which is which prevents two common mistakes: paying GLP prices for work that does not need it, and assuming exploratory discovery data will satisfy a regulator. When in doubt, ask the supplier whether a given study is exploratory or regulatory-grade before the work starts.
How does sourcing discovery services through BioBridgeX work?
BioBridgeX is a neutral marketplace for outsourced drug development. You describe what you need (the target class, the modality, the discovery services, the rough scope), and you are matched with qualified CRO and CDMO suppliers who can do that specific work. You compare them on capability, relevant experience, and transparent quotes, then choose. The platform is free for buyers; suppliers pay a flat 2% success fee after the buyer pays them, so the price you see is not padded with hidden buyer-side markups.
The structural advantage shows up when a discovery program needs more than one supplier, which it usually does. A single project might pull in a target-validation specialist, a screening CRO, a medicinal-chemistry group, and a structural-biology lab. Contracting and paying each one separately is slow and creates four points of administrative friction. Through BioBridgeX you compare quotes and contract directly with your chosen supplier, all in one place, with BioBridgeX acting as the neutral marketplace and not a party to the agreement.
Because the platform spans all indications and every modality, and the full lifecycle from discovery through preclinical, IND-enabling, clinical, and CMC, the same account carries forward as your program advances. The suppliers you find are vetted, their profiles are openly discoverable rather than locked behind a sales demo, and you keep one clean thread of contracting as you move from a discovery lead into the studies that follow.